MedicalCV drops heart valves in favour of AF (atrial fibrillation)
This article was originally published in Clinica
MedicalCV has decided to shift from the mechanical heart valves it has made for more than 20 years and focus instead on the faster-growing atrial fibrillation market. The Minneapolis, Minnesota company has struggled in an increasingly competitive valve market, and has reported "significant losses on modest revenues".
You may also be interested in...
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.